Personalis Reports Q4/FY25 Results, Secures Medicare Coverage, Projects 5x Clinical Revenue Growth in 2026
Summary
Personalis, Inc. announced Q4 and full-year 2025 financial results, highlighted by a 400% increase in clinical test volume, secured Medicare coverage for breast and lung cancer surveillance, and projected a five-fold increase in clinical revenue for 2026.
Key Events
-
Strong Clinical Growth
Clinical test volume surged 400% in 2025 to 16,233 tests, with Q4 volume up 41% sequentially over Q3 2025.
-
Pivotal Medicare Coverage Secured
Received Medicare coverage approval for breast and lung cancer recurrence surveillance, expected to be a key catalyst for clinical revenue generation.
-
Positive 2026 Outlook
Projected 2026 total revenue of $78.0 to $80.0 million, with clinical revenue expected to grow approximately five-fold to $10.0 to $11.0 million.
-
Fortified Balance Sheet
Ended 2025 with approximately $240 million in cash, cash equivalents, and short-term investments, including $109 million in net proceeds from an At-The-Market (ATM) sales program.
Analysis
This 8-K provides final Q4 and full-year 2025 financial results, confirming the preliminary announcement from January 8, 2026, and crucially offers detailed 2026 financial guidance. The most significant positive developments are the successful securing of Medicare coverage for breast and lung cancer surveillance, which is a major catalyst for future clinical revenue, and the projected five-fold increase in clinical revenue for 2026. While overall 2025 revenue declined and the company anticipates continued significant net losses and cash usage in 2026, the strategic progress in its core precision oncology business, particularly in minimal residual disease (MRD) testing, is substantial. The company's strong cash position, partly bolstered by a recent At-The-Market (ATM) program, provides the necessary capital to fund this commercial expansion. Investors should monitor the execution of the 'Win-in-MRD' strategy and the actual realization of the projected clinical revenue growth and Medicare reimbursement.
At the time of this filing, PSNL was trading at $8.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $801.9M. The 52-week trading range was $2.83 to $11.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.